Diversity and plasticity of mononuclear phagocytes

Gordon, Siamon; Mantovani, Alberto

doi:10.1002/eji.201141988

Cited by 105 publications

(83 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given this substantial difference in host-parasite interaction, the generation of a unique splenic CD19 + Breg in response to H. diminuta is plausible. Furthermore, descriptions of lymphocyte (including Bregs), innate adaptive lymphocytes, and macrophage subtypes (46,47) (22,24). Whereas the total number of splenic CD19 + /CD5 + cells was increased in infected mice, flow cytometry analyses did not reveal significant upregulation of canonical Breg markers on the HdBc (7 d ).…”

Section: Discussionmentioning

confidence: 99%

Splenic B Cells fromHymenolepis diminuta–Infected Mice Ameliorate Colitis Independent of T Cells and via Cooperation with Macrophages

Reyes

Wang

Fernando

et al. 2015

The Journal of Immunology

View full text Add to dashboard Cite

Helminth parasites provoke multicellular immune responses in their hosts that can suppress concomitant disease. The gut lumen-dwelling tapeworm Hymenolepis diminuta, unlike other parasites assessed as helminth therapy, causes no host tissue damage while potently suppressing murine colitis. With the goal of harnessing the immunomodulatory capacity of infection with H. diminuta, we assessed the putative generation of anti-colitic regulatory B cells following H. diminuta infection. Splenic CD19+ B cells isolated from mice infected 7 [HdBc(7d)] and 14 d (but not 3 d) previously with H. diminuta and transferred to naive mice significantly reduced the severity of dinitrobenzene sulfonic acid (DNBS)-, oxazolone-, and dextran-sodium sulfate–induced colitis. Mechanistic studies with the DNBS model, revealed the anti-colitic HdBc(7d) was within the follicular B cell population and its phenotype was not dependent on IL-4 or IL-10. The HdBc(7d) were not characterized by increased expression of CD1d, CD5, CD23, or IL-10 production, but did spontaneously, and upon LPS plus anti-CD40 stimulation, produce more TGF-β than CD19+ B cells from controls. DNBS-induced colitis in RAG1−/− mice was inhibited by administration of HdBc(7d), indicating a lack of a requirement for T and B cells in the recipient; however, depletion of macrophages in recipient mice abrogated the anti-colitic effect of HdBc(7d). Thus, in response to H. diminuta, a putatively unique splenic CD19+ B cell with a functional immunoregulatory program is generated that promotes the suppression of colitis dominated by TH1, TH2, or TH1-plus-TH2 events, and may do so via the synthesis of TGF-β and the generation of, or cooperation with, a regulatory macrophage.

show abstract

Section: Discussionmentioning

confidence: 99%

Splenic B Cells fromHymenolepis diminuta–Infected Mice Ameliorate Colitis Independent of T Cells and via Cooperation with Macrophages

Reyes

Wang

Fernando

et al. 2015

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Macrophages express several general markers, such as CD14, CD16, CD64, F4/80, CD68, CD11b and Ly6C in a heterogeneous fashion which only partially overlap between man and mouse [62,64,65]. Further, the combination of these markers to various other markers like chemokine receptors allow a sub-categorization of macrophages that is classically used to identify M1 and M2 like cells.…”

Section: Major Macrophage M1 and M2 Populations In The Mouse And In Hmentioning

confidence: 99%

Polarization of Macrophages in Metabolic Diseases

Rosendah¹

2015

J Clin Cell Immunol

View full text Add to dashboard Cite

Monocytes originate from progenitor cells in the bone marrow and traffic via the bloodstream to peripheral tissues. During both homeostasis and in responses to clear pathogens, circulating monocytes leave the bloodstream and migrate into tissues where they, following exposure to local growth factors, pro-inflammatory cytokines and microbial products, differentiate into macrophage or dendritic cell sub-populations. Type 1 diabetes (T1D) is a disease characterised by the elimination of the insulin producing β-cells in the pancreatic tissue through activation mainly of the adaptive immune system. In metabolic diseases, i.e. obesity, Type 2 diabetes (T2D) and diabetic complications, inflammation is mostly driven by macrophages and has been shown pivotal for disease progression even when blood glucose levels are well controlled. This review describes some current ideas and trends regarding the monocyte and macrophage involvement and their polarization in metabolic diseases that might open up novel therapeutic areas for the growing diabetic population.

show abstract

“…As most of the other cell types that populate the TME, they produce an assorted array of chemokines, cytokines, proteases, angiogenic and other growth factors. As unique property they possess the ability to phagozytose particular matter as dead cells, bacteria, viruses as well as artificial particles like liposomes, nanoparticles and other pharmaceutical drug carriers [157,[160][161][162][163][164][165][166][167][168][169][170][171][172][173]. Macrophages play a very important role in tumor development as they are a major component of the myeloid infiltrate in a tumor microenvironment.…”

Section: Macrophagesmentioning

confidence: 99%

A New Approach to Cancer Therapy: The Tumor Microenvironment as Target

Schwendener¹,

Mete²

2013

Frontiers in Clinical Drug Research - Anti-Cancer Agents

View full text Add to dashboard Cite

Solid tumors grow within a complex microenvironment composed of diverse cell types such as fibroblasts, endothelial cells, mast cells, macrophages and immune cells that are attracted by tumor cell derived factors and embedded in an extracellular matrix. Molecular and cellular interactions between epithelial cells and cells surrounding the tumor stroma promote growth, invasion and spread of tumors. To delay or impede tumor growth, the tumor microenvironment (TME) is increasingly being explored as a potential therapeutic target for which novel strategies are developed. lt;/pgt;lt;pgt; This article reviews how key interactions between tumor cells and surrounding mesenchymal and immune cells in the TME can promote tumor progression and it highlights cellular and molecular elements that might represent novel therapeutic targets. Special emphasis is given on therapies targeted towards tumor-associated macrophages. As main class of drugs the bisphosphonates are covered with their properties to repolarize a pro-tumorigenic, immunosuppressive environment to a tumor growth inhibiting and immunocompetent microenvironment. Properties and advantages of liposome-encapsulated bisphosphonates as macrophage depleting or modulating agents as well as the latest developments towards clinical applications of compounds targeting cellular and molecular components of the TME are described and reviewed. This article reviews how key interactions between tumor cells and surrounding mesenchymal and immune cells in the TME can promote tumor progression and it highlights cellular and molecular elements that might represent novel therapeutic targets. Special emphasis is given on therapies targeted towards tumor-associated macrophages. As main class of drugs the bisphosphonates are covered with their properties to repolarize a pro-tumorigenic, immunosuppressive environment to a tumor growth inhibiting and immunocompetent microenvironment. Properties and advantages of liposome-encapsulated bisphosphonates as macrophage depleting or modulating agents as well as the latest developments towards clinical applications of compounds targeting cellular and molecular components of the TME are described and reviewed.

show abstract

Diversity and plasticity of mononuclear phagocytes

Cited by 105 publications

References 26 publications

Splenic B Cells fromHymenolepis diminuta–Infected Mice Ameliorate Colitis Independent of T Cells and via Cooperation with Macrophages

Splenic B Cells fromHymenolepis diminuta–Infected Mice Ameliorate Colitis Independent of T Cells and via Cooperation with Macrophages

Polarization of Macrophages in Metabolic Diseases

A New Approach to Cancer Therapy: The Tumor Microenvironment as Target

Contact Info

Product

Resources

About